# Safety and Tolerability of GX-P1 in Healthy Male Volunteers

> **NCT04298749** · PHASE1 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** GX-P1 or Placebo (dose level 1)
- **DRUG:** GX-P1 or Placebo (dose level 2)
- **DRUG:** GX-P1 or Placebo (dose level 3)

## Key facts

- **NCT ID:** NCT04298749
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-11
- **Primary completion:** 2021-06-07
- **Final completion:** 2021-06-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04298749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04298749, "Safety and Tolerability of GX-P1 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04298749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*